MIV Therapeutics Highlights HAp Composite Coating Technologies at Leading Conference on Biomaterials; Better, Safer, More Biocompatible Stent Coating Technologies Presented at Recent International Society of Biomaterials Meeting

Business Wire, May 8, 2006

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, provided detailed background in two scientific poster presentations on its advanced, proprietary coating achievements at the prestigious annual international meeting of the Society of Biomaterials held in Pittsburgh, Penn., April 26-27.

At the conference, Dr. Quanzu Yang, Ph.D., a scientist at the University of British Columbia who works under the supervision of Dr. Tom Troczynski, Vice President of Coatings at MIVT, and Mr. Maurice Lien, BSc.Eng., Manager of R&D at MIVI Technologies, a wholly owned subsidiary of MIVT Therapeutics Inc., provided a poster presentation highlighting the Company's latest achievements in developing biopolymer-hydroxyapatite matrix composite coatings. The Company's proprietary composite formulation is designed to protect surrounding tissue from potentially harmful interactions with implanted metallic stents, while also serving as a substrate for next-generation drug-delivery solutions on vascular stents and other devices.

"Participating at the international conference of the Society of Biomaterials was an important opportunity to showcase some of our technology alongside other cutting-edge medical technologies from around the world," said Dr. Troczynski. "The poster presentation was very well-received and helped to increase scientific awareness about the superior biocompatible potential of HAp composite coatings on medical implants. The data on HAp are exciting, and we are committed to bringing this improved coating technology to the market."

MIV Therapeutics is a leader in the research and development of a novel organic material, called Hydroxyapatite (HAp), which is designed to provide medically needed advantages over the current polymer coatings used in the growing, multibillion-dollar worldwide marketplace for vascular stents and other medical devices. In contrast to polymer, HAp is a naturally occurring substance, found in human bone and teeth.

Ongoing studies at MIVT have consistently demonstrated HAp's potential for superior safety and biocompatibility as a coating material on stents and other medical devices. Under the terms of a Collaborative Research Agreement with the University of British Columbia, MIV Therapeutics works closely with UBC to develop HAp medical applications and technologies.

About the Society for Biomaterials Conference

The U.S.-based Society for Biomaterials is a professional society which promotes advances in all phases of materials research and development by encouragement of cooperative educational programs, clinical applications and professional standards in the biomaterials field. Attendees of the annual Society for Biomaterials meeting reflect the multidisciplinary nature of this field, and work every day to advance these topic areas by applying many of the lessons learned at the SFB Meeting to new clinical approaches.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp), which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.